Torsten Goesch
MD, MBA, PhD,
Chairman of the Board
since 2015
|
Achim Kaufhold
MD,
Board Member
since 2021
|
Marianne Kock
MSc, MBA,
Board member
since 2021
|
- Dependent in relation to the company, independent in relation to its senior executives and major shareholders.
- Dr. Torsten Goesch has been Director of Rosetta Capital’s secondary life science investments since 2002
- Has served as the General Manager for the German Speaking Countries at Biogen from 1997-1999
- Commercial Head of Merck KGaA’s worldwide generics drug business Merck Generics
|
- Independent in relation to the company, to its senior executives and major shareholders.
- Currently serves as CMO of Hansa Biopharma.
- Has previously served as CEO of Affitech and Pharmexa (both companies merged)
- CMO of companies such as Basilea Pharmaceutica, Chiron (acquired by Novartis) and Berna Biotech (now Johnson & Johnson)
|
- Independent in relation to the company, to its senior executives and major shareholders.
- Currently serves as General Manager at Ferring Pharmaceuticals’ IPC Development Unit in Copenhagen.
- Board member of Ferring Pharmaceutical (DK), Syntese (DK), Izvarino Pharma (Rus), NanoPharm (Rus) and Asarina (SE)
- Previously, board member of Fertin Pharma (DK), Bionor Pharma (NO), Egalet (DK), Forward Pharma (DK) and Gastrotech Pharma (DK)
|
- Doctor of Medicine (MD) and Ph.D. from Heinrich Heine University Düsseldorf
- Master of Management (MBA) from Northwestern University’s
J.L. Kellogg Graduate School of Management
|
- Doctor of Medicine from the University of Cologne and holds a professorship in Medical Microbiology and Infectious Diseases at the University of Aachen, Germany
|
- Master’s degree in Pharmacy from Danish University of Pharmacy
- Executive Master’s degree in Business Administration from Scandinavian International Management Institute
|
